Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis

Journal of Medical Investigation

Volumn 53, Issue 1-2, 2006, Pages 87-94

  Koshiba, Kunihiko ^a   Nomura, Masahiro ^a   Nakaya, Yutaka ^a   Ito, Susumu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Adipocytokines; Atherosclerosis; Glimepiride; Insulin resistance

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; GLIBENCLAMIDE; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANKLE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL;

ADIPOCYTES; AGED; ATHEROSCLEROSIS; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 33645801431     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.53.87     Document Type: Article

References (28)

1. Draeger KE, Wernicke-Panten K, Lomp HJ, Schuler E, Rosskamp R: Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride(Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 28: 419-425, 1996
2. Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A, Nomura N, Miyazaki A, Iguchi A: Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 26: 285-289, 2003
3. Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M, Kashiwabara H, Yokota K, Suzuki M, Kurihara S, Awata T, Katayama S: Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Res Clin Pract 68: 250-257, 2005
4. Lehmann ED: Noninvasive measurements of aortic stiffness: methodological considerations. Pathol Biol (Paris) 47: 716-730, 1999
5. O'Rourke MF, Mancia G: Arterial stiffness. J Hypertens 17: 1-4, 1999
6. Harada S, Takeda K: Pulse wave velocity (PWV). Nippon Rinsho 62 (in Japanese): 1136-1142, 2004
7. Purnell JQ, Weyer C: Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2: 33-47, 2003
8. Muller G, Satoh Y, Geisen K: Extrapancreatic effects of sulfonylureas-a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 28(Suppl):S115-137, 1995
9. Hatao K, Kaku K, Matsuda M, Tsuchiya M, Kaneko T: Sulfonylurea stimulates liver fructose-2, 6-bisphosphate formation in proportion to its hypoglycemic action. Diabetes Res Clin Pract 1: 49-53, 1985
10. Takada Y, Takata Y, Iwanishi M, Imamura T, Sawa T, Morioka H, Ishihara H, Ishiki M, Usui I, Temaru R, Urakaze M, Satoh Y, Inami T, Tsuda S, Kobayashi M: Effect of glimepiride (HOE 490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse. Eur J Pharmacol 308: 205-210, 1996
11. Muller G, Wied S, Wetekam EM, Crecelius A, Unkelbach A, Punter J: Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulphonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade. Biochem Pharmacol 48: 985-996, 1994
12. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295, 2002
13. Ozes ON, Akca H, Mayo LD, Gustin JA Maehama T, Dixon JE, Donner DB: A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA 98: 4640-4645, 2001
14. Jain R, Police S, Phelps K, Pekala PH: Tumour necrosis factor-alpha regulates expression of the CCAAT-enhancer-binding proteins (C/EBPs) alpha and beta and determines the occupation of the C/EBP site in the promoter of the insulin-responsive glucose-transporter gene in 3T3-L1 adipocytes. Biochem J 338 (Pt 3):737-743, 1999
15. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100: 2473-2476, 1999
16. Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I: Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 280: 23653-23659, 2005
17. Inukai K, Watanabe M, Nakashima Y, Takata N, Isoyama A, Sawa T, Kurihara S, Awata T, Katayama S: Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun 328: 484-490, 2005
18. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H: Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 22: 818-822, 1999
19. Mod Y, Komiya H, Kurokawa N, Tajima N: Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity. Diabetes Obes Metab 6: 28-34, 2004
20. Martin S, Kolb H, Beuth J, van Leendert R, Schneider B, Scherbaum WA: Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 46: 1611-1617, 2003
21. Weitgasser R, Lechleitner M, Luger A, Klingler A: Effects of glimepiride on HbA(1 c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study. Diabetes Res Clin Pract 61: 13-19, 2003
22. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102: 1296-1301, 2000
23. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96: 1723-1732, 2000
24. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103: 1057-1063, 2001
25. Derosa G, Franzetti I, Gadaleta G, Ciccarelli L, Fogari R: Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. Diabetes Nutr Metab 17: 143-150, 2004
26. Ueba H, Kuroki M, Hashimoto S, Umemoto T, Yasu T, Ishikawa S, Saito M, Kawakami M: Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Atherosclerosis 183: 35-39, 2005
27. Yang B, Tian H, Ren Y, Tong N, Yu H, Han L, Ran X: The change of atherogenic index of plasma (AIP) level in type 2 diabetic pedigrees and the response of AIP to Acarbose or Glimepiride in therapy of type 2 diabetes mellitus. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 22 (English abstract): 560-4, 2005
28. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Centers for Disease Control and Prevention; American Heart Association.: Markers of inflammation and cardiovascular disease:application to clinical and public health practiced statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511, 2003